摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-methoxyphenyl)-N-(5-nitro-1,3-thiazol-2-yl)propanamide

中文名称
——
中文别名
——
英文名称
3-(4-methoxyphenyl)-N-(5-nitro-1,3-thiazol-2-yl)propanamide
英文别名
——
3-(4-methoxyphenyl)-N-(5-nitro-1,3-thiazol-2-yl)propanamide化学式
CAS
——
化学式
C13H13N3O4S
mdl
MFCD07134917
分子量
307.33
InChiKey
QOOKTOYWEDZCMO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.2
  • 重原子数:
    21
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.23
  • 拓扑面积:
    125
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES DE -1,3-THIAZOLE SUBSTITUE EN POSITION 2
    申请人:ASTRAZENECA AB
    公开号:WO2003089419A1
    公开(公告)日:2003-10-30
    The present invention relates to new compounds of formula I, Wherein Y is NR4CONR4, NR4CO, or NR4; R1 is nitro or COR5; R2 is hydrogen or NH2; R3 is C1-6alkyl or C0-6alkylaryl wherein C0-6alkylaryl may be substituted by A; R4 is hydrogen; R5 is C1-6alkyl; A is independently selected from halo, OR6 and C1-6alkyl; R6 is C1-6alkyl; provided that the compound is not N-(4-Methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea as a free base or a salt thereof as well as a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    本发明涉及公式I的新化合物,其中Y为NR4CONR4、NR4CO或NR4;R1为硝基或COR5;R2为氢或NH2;R3为C1-6烷基或C0-6烷基芳基,其中C0-6烷基芳基可以被A取代;R4为氢;R5为C1-6烷基;A独立地选自卤素、OR6和C1-6烷基;R6为C1-6烷基;前提是该化合物不是N-(4-甲氧基苯甲基)-N'-(5-硝基-1,3-噻唑-2-基)的自由碱或其盐,以及其制备方法、含有所述治疗活性化合物的药物配方以及所述活性化合物在治疗中的使用。
  • 2-substituted-1,3-thiazole compounds
    申请人:Berg Stefan
    公开号:US20050119321A1
    公开(公告)日:2005-06-02
    The present invention relates to new compounds of formula I, Wherein Y is NR 4 CONR 4 , NR 4 CO, or NR 4 ; R 1 is nitro or COR 5 ; R 2 is hydrogen or NH 2 ; R 3 is C 1-6 alkyl or C 0-6 alkylaryl wherein C 0-6 alkylaryl may be substituted by A; R 4 is hydrogen; R 5 is C 1-6 alkyl; A is independently selected from halo, OR 6 and C 1-6 alkyl; R 6 is C 1-6 alkyl; provided that the compound is not N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea as a free base or a salt thereof as well as a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    本发明涉及公式I的新化合物,其中Y为NR4CONR4、NR4CO或NR4;R1为硝基或COR5;R2为氢或NH2;R3为C1-6烷基或C0-6烷基芳基,其中C0-6烷基芳基可以被A取代;R4为氢;R5为C1-6烷基;A是独立选择的卤素、OR6和C1-6烷基;R6为C1-6烷基;所述化合物不是N-(4-甲氧基苯基)-N'-(5-硝基-1,3-噻唑-2-基)的游离基或其盐,以及制备它们的过程、含有所述治疗活性化合物的制药组合物和所述活性化合物在治疗中的应用。
  • New 2-substituted - 1,3-thiazole compounds
    申请人:Berg Stefan
    公开号:US20060194854A1
    公开(公告)日:2006-08-31
    The present invention relates to new compounds of formula I, Wherein Y is NR 4 CONR 4 , NR 4 CO, or NR 4 ; R 1 is nitro or COR 5 ; R 2 is hydrogen or NH 2 ; R 3 is C 1-6 alkyl or C 0-6 akylaryl wherein C 0-6 alkylaryl may be substituted by A; R 4 is hydrogen; R 5 is C 1-6 alkyl; A is independently selected from halo, OR 6 and C 1-6 alkyl; R 6 is C 1-6 alkyl; provided that the compound is not N-(4-Methoxybenzyl)-N′-(5-nitro-1,3-thiazol-2-yl)urea as a free base or a salt thereof as well as a process for their preparation, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
    本发明涉及化合物I的新化合物,其中Y为NR4CONR4,NR4CO或NR4; R1为硝基或COR5; R2为氢或NH2; R3为C1-6烷基或C0-6烷基芳基,其中C0-6烷基芳基可以被A取代; R4为氢; R5为C1-6烷基; A独立选择自卤,OR6和C1-6烷基; R6为C1-6烷基; 前提是该化合物不是游离基或盐形式的N-(4-甲氧基苯甲基)-N'-(5-硝基-1,3-噻唑-2-基),以及制备它们的过程,含有该治疗活性化合物的制药配方以及在治疗中使用该活性化合物。
  • NEW 2-SUBSTITUTED -1,3-THIAZOLE COMPOUNDS
    申请人:AstraZeneca AB
    公开号:EP1499601A1
    公开(公告)日:2005-01-26
  • METHODS AND COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISORDERS
    申请人:Rubin Lee
    公开号:US20120010178A1
    公开(公告)日:2012-01-12
    Methods, compounds and compositions for promoting motor neuron survival and the treatment of a neurodegenerative disorders such as Spinal Muscular Atrophy (SMA) are described herein.
查看更多